Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio

Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer 
Immunology Portfolio 
SAN DIEGO, CA -- (Marketwired) -- 01/24/14 --  Adamis Pharmaceuticals
Corporation (NASDAQ: ADMP) announced an important addition to its
intellectual property with receipt of a Notice of Allowance of patent
claims supporting its cancer immunotherapy portfolio in the United
States. Notice of Allowance is the final step in the issuance of a
patent. The company believes that this patent will significantly
strengthen Adamis' cancer immunotherapy patent portfolio and will
further support its TeloB-VAX vaccine technology. Claims to a patent
entitled "Composition and Method for Inducing and Enhancing a
Telomerase Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte
Response" have been allowed. These include claims for peptides that
induce or enhance a cytotoxic T cell immune response against the
human tumor antigen telomerase reverse transcriptase.  
About TeloB-VAX 
TeloB-Vax is an important asset in Adamis' oncology pipeline. The
technology forming the basis for the patent was discovered and
developed by Maurizio Zanetti, M.D., at the University of California,
San Diego (UCSD). In 2011, Adamis licensed this technology from the
Regents of the University of California as well as a complementary
patent, "Cancer Immunotherapy and Diagnosis Using Universal Tumor
Associated Antigens, Including Human Telomerase Reverse
Transcriptase," from the Dana-Farber/ Harvard Cancer Center.  
These technologies constitute the basis of a novel cell-based cancer
vaccine product candidate, TeloB-VAX, which has been shown to
activate the body's natural defense system to stimulate an immune
response against one of cancer's most common tumor markers,
telomerase. The vaccine utilizes the patient's own B cells as antigen
producing and antigen presenting cells. The B cells present
telomerase peptides to the T cells that then expand and search out
and kill prostate cancer cells.  
Dr. Zanetti has said of the TeloB-Vax vaccine technology, "It may
represent one of the first concrete opportunities to program the
immune system to induce killer lymphocytes to combat cancer cells,
whether these are adult differentiated cells or progenitor cancer
stem cells. Since telomerase is increased in over 85% of all cancers,
the vaccine could potentially be used to treat multiple cancer types,
such as breast, lung, and colon cancer. I believe that it can truly
be considered a platform therapeutic vaccine technology." Telomerase
was the subject of the Nobel Prize for Medicine in 2009. 
Adamis' TeloB-VAX vaccine technology is composed of the patient's own
circulating B lymphocytes harboring a unique patented engineered
plasmid DNA. The transfection procedure is "spontaneous," requiring
no facilitating molecules or devices. After 60 minutes of incubation
with the plasmid, the patient's own cells can be re-infused.  
In a Phase 1 study already completed at UCSD in castrate resistant
prostate cancer patients, the vaccine product was shown to be safe,
non-toxic and immunogenic. Two injections of TeloB-VAX, spaced one
month apart, was shown to induce a specific CD8 T cell response. More
important, the T cells were shown to specifically kill prostate
cancer cells.  
Dr. Dennis J. Carlo, President and CEO of Adamis Pharmaceuticals,
stated, "At the J.P. Morgan Healthcare Conference last week,
immunotherapy occupied much of the spotlight. We believe that our
telomerase therapeutic cancer vaccine could prove to be important in
the treatment of cancer. Harnessing and directing a systemic immune
response that targets tumor cells throughout the body might be
possible through the use of our vaccine technology. Telomerase is
probably the closest to any universal tumor marker that we know of
today." 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. The company's
current specialty pharmaceutical product candidates include the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The company's vaccine product candidates and cancer drug
product candidates under research and development include TeloB-VAX,
a cell-based therapeutic cancer vaccine and three drugs, APC-100,
APC-200, and APC-300, for the treatment of prostate cancer. 
Recent, previously-reported developments include the following: 


 
--  December 13 - Adamis commenced trading on Nasdaq.
    
    
--  December 18 - Adamis announced the closing of its underwritten public
    offering of common stock.
    
    
--  December 27 - Adamis announced the completion of the acquisition of
    Taper dry powder inhaler technology.
    
    
--  January 13 - Adamis announced full exercise of underwriter's
    over-allotment option in connection with the public offering of common
    stock.

  
Forward Looking Statements 
This press release may contain forward-looking statements within the
meaning of federal securities laws that relate to future events or
our future results of operations, including, but not limited to the
following statements: our ability to successfully develop the
TeloB-VAX product candidate or any other product candidate; the
safety, efficacy or therapeutic impact of any product candidate that
we may develop; our ability to fund future product development and
business operations; the intellectual property protection that may be
afforded by any patents or patent applications relating to the
company's technology; and the results of any future preclinical or
clinical trials that may be conducted concerning TeloB-VAX or any
other product candidate. Forward looking statements involve risks and
uncertainties, and are not guarantees of future performance. Actual
events or results may differ materially from those contemplated by
such forward looking statement. Forward looking statements assume
that we will have sufficient funding to support the activities
contemplated by such forward looking statements and that there are no
significant unexpected developments or events that delay or prevent
such activities from occurring. There can be no assurance that this
will be the case. You should not place undue reliance on any
forward-looking statements. Certain of these risks, uncertainties,
and other factors are described in greater detail in Adamis' filings
from time to time with the SEC, which Adamis strongly urges you to
read and consider, all of which are available free of charge on the
SEC's web site at http://www.sec.gov. Except as required by law,
Adamis expressly disclaims any obligation to update any
forward-looking statements.  
Adamis Contacts 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com 
Mark Gundy
Capital Group Communications, Inc.
(972) 240-1873
mark.gundy@capitalgc.com